Biogen is investing $1.15 billion in Chris Viehbacher’s strategy to diversify th...
Novo Nordisk aims to be the first to launch a weekly insulin product, particular...
The recently published study in the New England Journal of Medicine, as well as ...
Swedish pharma company Vicore announced the results of its phase 2a AIR trial fo...
AstraZeneca is reportedly planning to build a $1.5 billion facility in Singapore...
In a phase 2 study on idiopathic pulmonary fibrosis (IPF), Endeavor BioMedicines...
Results from two clinical trials showed that a once-weekly version of insulin de...
After the disappointing outcome of early-stage trials for their antisense drug B...
Recently, the U.S. Food and Drug Administration (FDA) approved Imdelltra, a new ...
The rapidly developing area of pulsed field ablation is gaining momentum all ove...
The U.S. health regulator, FDA, has now allowed Eisai and Biogen to provide data...
Roche, one of the first companies to provide an HPV self-collection option in th...
The FDA has given the go-ahead for Bristol Myers Squibb’s Breyanzi – a cancer ce...
MacroGenics’s safety concerns have continued throughout phase 2 of the project. ...
The Phase III KEYNOTE-B21 (ENGOT-en11/GOG-3053) research study, which aimed to t...
As France prepares for its annual ‘Choose France’ business summit, the pharmaceu...
